Cardioprotective Effect of Sodium Ferulate in Diabetic Rats by Xu, Xiaohong et al.
Int. J. Med. Sci. 2012, 9 
 
 
http://www.medsci.org 
291 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2012; 9(4):291-300. doi: 10.7150/ijms.4298 
Research Paper 
Cardioprotective Effect of Sodium Ferulate in Diabetic Rats 
Xiaohong Xu1#, Haijuan Xiao2#, Jiangpei Zhao3, Tongfeng Zhao2  
1.  Department of Endocrinology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, PR China.  
2.  Department of Geriatrics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, PR China.  
3.  Department of Geriatrics, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310000, PR China.  
# Xiaohong Xu and Haijuan Xiao contributed equally to this work. 
 Corresponding author: Tongfeng Zhao, Ph.D., Department of Geriatrics, the Second Affiliated Hospital, School of Medi-
cine,  Zhejiang  University,  Hangzhou  310000,  PR  China.  Tel:  +86  571  887784720;  Fax:  +86  571  87022660;  E-mail: 
zhaotongfeng@yahoo.com.cn 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2012.02.28; Accepted: 2012.05.29; Published: 2012.06.05 
Abstract 
Reactive oxygen species (ROS) play important roles in the occurrence and development in 
diabetic cardiomyopathy (DC). Ferulic acid is one of the ubiquitous compounds in diet. So-
dium ferulate (SF) is its sodium salt. SF has potent free radical scavenging activity and can 
effectively scavenge ROS. The study investigated the effect of SF on cardioprotection in di-
abetic  rats.  The  diabetic  rats  induced  by  streptozotocin  (STZ)  were  treated  with  SF 
(110mg/kg) by gavage per day for 12 weeks. Results showed that the levels of nitric oxide 
(NO) and superoxide dismutase (SOD) activity in plasma and myocardium in SF-treated group 
were significantly higher than those in diabetic control group. The levels of malondialdehyde 
(MDA) in plasma and myocardium in SF-treated group were significantly lower than those in 
diabetic control group. Expression of connective tissue growth factor (CTGF) in myocardium 
in SF-treated group was apparently lower than that in diabetic control group. Compared with 
normal control group, electron micrographs of myocardium in diabetic control group showed 
apparently abnormality, while that was significantly ameliorated in SF-treated group. The study 
demonstrated that SF has a cardioprotective effect via increasing SOD activity and NO levels 
in plasma and myocardium, inhibiting oxidative stress in plasma and myocardium, and inhib-
iting the expression of CTGF in myocardium in diabetes rats. 
Key words: diabetic cardiomyopathy, sodium ferulate, oxidative stress, nitric oxide, superoxide 
dismutase, connective tissue growth factor. 
Introduction 
Diabetic  cardiomyopathy  (DC)  is  the  most 
common  serious  complication  of  diabetes  mellitus.1 
DC has become one of the leading causes of the in-
creased mortality in both type 1 and type 2 diabetes. 
Clinically, DC can occur without major vascular le-
sions, suggesting a primary role for direct effects of 
diabetes on cardiomyocytes.1,2 Previous studies have 
demonstrated  oxidative  damage  and  myocardial  fi-
brosis play important roles in the occurrence and de-
velopment of DC.3,4 
Oxidative stress occurs when there is a serious 
imbalance  between  generation  of  reactive  oxygen 
species (ROS) and its clearance by body’s endogenous 
antioxidative  defenses.5  ROS  include  several  sorts, 
such  as  superoxide  anion,  hydrogen  peroxide,  per-
oxynitrite, and hydroxyl.6 Reports have showed there 
are overproduction of ROS and impairment of anti-
oxidant  enzymes  activities,  such  as  superoxide  dis-
mutase (SOD), in the heart of diabetic animal model.7,8 
Recent studies have shown that antioxidative medi-
Ivyspring  
International Publisher   Int. J. Med. Sci. 2012, 9 
 
http://www.medsci.org 
292 
cine  include  probucol,  N-acetylcysteine,  SOD  can 
protect the heart from diabetes-induced damage.4,7,9,10  
Nitric oxide (NO) also plays important roles in 
the tissue damage induced by oxidative stress.5 NO 
normally  is  produced  by  endothelial  nitric  oxide 
synthase (eNOS), but is also produced by inducible 
nitric oxide synthase (iNOS) in the target tissues un-
der  inflammatory  states.5  NO  can  interact  with  su-
peroxide  anion  to  form  peroxynitrite.5  Peroxynitrite 
can  cause  nitrosative  stress  and  has  dramatic  pro-
pathogenic effects in tissues and organs.4,5  
Sodium ferulate (SF) is sodium salt of ferulic acid 
(Fig. 1). Ferulic acid, 4-hydroxy-3-methox-ycinnamic 
acid, is a sort  of plant phenolic compound (Fig. 1). 
Ferulic acid is one of the ubiquitous compounds in 
diet, especially rich in grains, fruits, vegetables and 
beverage.11,12  Moreover,  it  is  also  the  effective  com-
ponent of Chinese medicinal herbs Ligusticum walliichi 
(Chuanxiong) which has long been used for menoxe-
nia, amenia, cardiovascular and cerebrovascular dis-
eases in China.13 Ferulic acid, because of its phenolic 
nucleus and unsaturated side chain can readily form a 
resonance stabilized phenoxy radical, has potent free 
radical scavenging activity and can effectively scav-
enge ROS.12 Ferulic acid is unstable and can’t be easily 
solved  in  water.  Compared  with  ferulic  acid,  SF  is 
more stable and more easily solved in water. So SF 
was used to treat diabetic rats in the present study. 
Our previous study showed that SF exhibits its pro-
tective effect on kidney in diabetic rats, which is at-
tributed to its roles of increasing antioxidant enzymes 
activity, inhibiting oxidative stress.14 
Although SF and ferulic acid exhibit beneficial 
effects in many diseases, whether SF or ferulic acid 
has beneficial effects in DC is still unclear. In the pre-
sent  study,  diabetic  rats  induced  by  streptozotocin 
(STZ) were orally administered with SF, and the car-
dioprotective effect of SF was investigated. 
 
 
 
Figure 1: Chemical structures of ferulic acid and sodium ferulate. 
 
 
Materials and methods  
Animals 
Male  SD  rats  with  the  age  of  8-10  weeks  old 
(weighing  230-260g)  were  purchased  from  Animal 
Experimental Center of Zhejiang University. 
Drugs and reagents 
STZ  were  purchased  from  Sigma  Company, 
USA. 3,3-diaminobenzidine tetrahydrochloride (DAB) 
was bought from Sigma Chemical Co., USA. Chloral 
hydrate was purchased from Fluka, USA. SOD assay 
kits  (Intra-assay  CV:  5.05%;  Inter-assay  CV:  3.32%), 
malondialdehyde (MDA) assay kits (Intra-assay CV: 
3.5%; Inter-assay CV: 4.11%), and NO assay kits (In-
tra-assay  CV:  2.0%;  Inter-assay  CV:  5.19%),  protein 
quantification  kits  were  purchased  from  Jiancheng 
Bio-engineering  Company,  Nanjing,  China.  Blood 
glucose  assay  kit  was  purchased  from  Changcheng 
Clinical Reagents Company, Baoding, Hebei, China. 
All assay kits were used according to the manufac-
turers’ instructions strictly. SF was kindly provided 
from  Limin  pharmaceutical  Company,  Guangdong, 
China. Goat anti-rat connective tissue growth factor 
(CTGF) polyclonal antibody (sc-14939), rabbit anti-rat 
iNOS  polyclonal  antibody  (sc-649),  mouse  anti-goat 
IgG  (sc-2489)  and  mouse  anti-rabbit  IgG  (sc-2491) 
were purchased from Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA.  
Study design 
Rats  were  housed  at  23-25°C  in  a  12-hour 
light/dark cycle with access to standard powdered rat 
chow  and  normal  water.  The  scientific  project,  in-
cluding animal care was supervised and approved by 
Animals  Ethics  Committee  of  the  Second  Affiliated 
Hospital, Zhejiang University. Diabetes was induced 
in SD rats by a single STZ injection (60 mg/kg i.p., 
dissolved  in  citrate  buffer)  after  overnight  fast.  72h 
after injection, the rats with blood glucose higher than 
16.65mmol/L  were  considered  as  successfully  dia-
betic model rats. All normal control group rats were 
treated  with  citrate  buffer.  Diabetic  animals  were 
randomized  into  diabetic  control  group  and Int. J. Med. Sci. 2012, 9 
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SF-treated group. Rats in the SF-treated group were 
treated with SF (110mg/kg) by gavage per day.14 Rats 
in the diabetic control group and the normal control 
group were treated with the same volume of normal 
saline by gavage per day. Every group included 10 
rats. All rats in those three groups were not treated 
with insulin and other hypoglycemic agent, and could 
drink and eat freely in the experiment period. After 12 
weeks, rats in the three groups were weighed. Rats 
were anesthetized by intraperitoneal (i.p.) injection of 
350mg/kg chloral hydrate, the thoracic cavities were 
opened,  and  blood  samples  were  directly  obtained 
from the hearts.15 Plasma were separated and stored 
in freezer (-80°C) for analysis. Heart of every rat was 
lavaged  with  icecold  normal  saline,  removed  and 
weighed. Part of left ventricular tissue was fixed with 
10% formalin for immunohistochemical examination. 
Four rats were randomly selected from every group. 
Part of left ventricular tissue of these rats was used for 
electron microscope assay. The remaining myocardial 
tissues were preserved in -80°C freezer for analysis.  
Heart weight/Body weight (HW/BW) and 
blood glucose assay 
HW/BW  was  calculated  according  to  the  for-
mula: HW/BW=100×[Heart weight (g)/Body weight 
(g)]. Blood glucose was assayed by method of glucose 
oxidase. 
Determination of SOD activity, MDA, and NO 
SOD activity in plasma and myocardium were 
assayed by the method of xanthine oxidase according 
to the kit’s instruction. The method is based on that 
SOD can inhibit superoxide anion reacting with hy-
droxylamine to generate nitrite. The content of SOD 
can be determined according to the formula provided 
by the kit. SOD results in plasma and myocardium 
were expressed as nitrite unit per milliliter (NU/ml) 
and nitrite unit per milligram protein (NU/mg pro-
tein) respectively. 
MDA is the end product of lipid peroxidation. 
The content of MDA can indicate the extent of lipid 
peroxidation. MDA in plasma and myocardium were 
assayed by  thiobarbituric  acid method according to 
the  kit’s  instruction.  The  method  is  based  on  that 
MDA can react with thiobarbituric acid to produce a 
red complex which has a peak absorbance at 532nm. 
The  content  of  MDA  can  be  determined  by  this 
method.  MDA  results  in  plasma  and  myocardium 
were expressed as nanomoles per milliliter (nmol/ml) 
and  nanomoles  per  milligram  protein  (nmol/mg 
protein) respectively.  
NO in plasma and myocardium were assayed by 
nitrate  reductase  method  according  to  the  kit’s  in-
struction. NO is unstable and easily oxidized to gen-
erate  nitrite and nitrate. NO level is determined by 
measuring the total levels of nitrite/ nitrate. Samples 
were incubated with nitrate reductase to convert all 
nitrate to nitrite. Total nitrite/nitrate was assessed by 
spectrophotometer  at  550  nm.  NO  results  were  in 
plasma  and  myocardium  were  expressed  as  nano-
moles  per  milliliter  (nmol/ml)  and  nanomoles  per 
milligram protein (nmol/mg protein) respectively. 
10%  (w/v)  myocardial  tissue  homogenate  was 
made  by  homogenizer  in  ice  bath.  Sample  protein 
content was quantified by the method of Coomassie 
brilliant blue with BSA as the standard.  
Immunohistochemical assay for CTGF and 
iNOS 
Paraffin-embedded left ventricular tissue blocks 
were  sectioned  at  4μm  (8  rats  per  group),  and  we 
stained 8 sections per group for CTGF and iNOS re-
spectively.  The  sections  were  deparaffinized,  rehy-
drated,  treated  with  target  retrieval  solution,  and 
blocked with 3% hydrogen peroxide. After blocking 
with 10% normal goat serum, the slides were incu-
bated  with  primary  antibody  (both  in  a  1:500  dilu-
tion). The slides were then incubated with mouse an-
ti-goat IgG (in a 1:400 dilution for CTGF) and goat 
anti-rabbit IgG (in a 1:400 dilution for iNOS) labeled 
by  biotin  and  further  incubated  with  streptavidin 
peroxidase solution. The staining was visualized by 
reaction with DAB chromogen. Slides were counter-
stained with hematoxylin, washed in running water 
and mounted with resinous mounting medium. Posi-
tive staining was shown in yellow.  
For quantification (8 sections per group respec-
tively)  of  immunohistochemical  staining  for  CTGF 
and iNOS, three random 100× microscopic fields per 
slide  were  photographed  using  a  standard  Olypus 
DP71 Light Microscope.16 Then a computer imaging 
analysis software Image-Pro Plus 6.0 (Media Cyber-
netics,  America)  was  used  for  digital  photographs 
analysis  by  calculation  of  integrated  optical  density 
(IOD)  referencing  the  method  introduced  previous-
ly.16,17 IOD, the integral calculus of the stained area 
times the intensity of stain in each pixel in the area, 
indicates the total amount of staining material in that 
area.17  
Ultrastructural examination by electron mi-
croscope 
Left ventricular myocardial tissues were cut as 
the size of about 1mm3 (4 rats per group). Then myo-
cardial  tissues  were  fixed  in  2.5%  glutaraldehyde, 
followed  in  1%  osmic  acid.  After  dehydration  by 
ethanol and embedded by epoxy resins, the myocar-Int. J. Med. Sci. 2012, 9 
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dial tissue were sectioned at 70 nm. The sections (4 
sections per group) were stained with uranyl acetate 
and lead citrate, and examined in JEM-1230 (Japan) 
transmission electron microscope. 
Statistical analysis 
Data were expressed as means ± SD values. Data 
were  analyzed  using  one-way  analysis  of  variance 
(ANOVA)  and  secondary  analysis  for  significance 
with the Turkey-Kramer post test. All analyses were 
performed using SPSS version 11.0 (SPSS Inc., USA). P 
<0.05 was considered statistically significant. 
Results  
Effect of SF on HW, BW, HW/BW, and blood 
glucose 
In the ninth week of our experiment, we found 
that two rats in normal control group were dead; we 
neither  dissected  them  nor  searched  for  possible 
causes since we thought that two rats’ death in normal 
control group would not affect our experiment accu-
racy at that time. Besides, we lost two rats in diabetic 
control  group  and  two  rats  in  SF-treated  group  re-
spectively, which might be as the result of their hy-
perglycemic conditions. The BW and HW in the nor-
mal  control  group  were  significantly  higher  than 
those  in  the  diabetic  control  and  SF-treated  group 
(P<0.01).  No  significant  difference  in  BW  and  HW 
were  found  between  the  SF-treated  group  and  the 
diabetic control group (P>0.05). HW/BW in the nor-
mal control group was significantly lower than that in 
the diabetic control and SF-treated group (P<0.05). No 
significant difference in HW/BW was found between 
the SF-treated group and the diabetic control group 
(P>0.05). Blood glucose in the diabetic control group 
and  the  SF-treated  group  were  significantly  higher 
than that in the normal control group (P<0.01), but no 
significant  difference  was  found  between  the 
SF-treated  group  and  the  diabetic  control  group  (P 
>0.05) (Table 1).  
Effect of SF on SOD activity, MDA and NO 
levels in plasma and myocardium  
Plasma  SOD  activity  in  the  diabetic  control 
group were significantly lower than that in the normal 
control  group  (P<0.01).  Plasma  SOD  activity  in  the 
SF-treated group were significantly higher than that 
in  the  diabetic  control  group  (P<0.05).  Myocardial 
SOD activity in the diabetic control group were sig-
nificantly lower than that in the normal control group 
(P<0.01).  Myocardial  SOD  activity  in  the  SF-treated 
group were significantly higher than that in the dia-
betic control group (P<0.05) (Fig. 2). 
Plasma MDA levels in the diabetic control group 
were significantly higher than that in both the normal 
control  group  (P<0.01)  and  the  SF-treated  group 
(P<0.05). Myocardial MDA levels in the diabetic con-
trol group were significantly higher than that in both 
the normal control group (P<0.01) and the SF-treated 
group (P<0.01) (Fig. 3).  
 
Table 1 Effect of sodium ferulate on HW, BW, HW/BW, and blood glucose. 
Group  Normal control group  Diabetic control group  SF-treated group 
HW (g)  1.450.13  1.190.20**  1.160.16** 
BW (g)  476.2552.19  347.8870.8**  355.2545.78** 
HW/BW (×100)  0.310.03  0.350.04*  0.330.04 
Blood glucose (mmol/L)  5.250.82  27.561.47**  27.932.72** 
Values are expressed as means ± SD (n=8 rats/group) 
HW, heart weight; BW, body weight; HW/BW, heart weight/body weight 
* P <0.05, ** P <0.01 compared with normal control group 
 
Table 2 Effect of sodium ferulate on SOD activity, MDA levels and NO levels in plasma and myocardium. 
Groups  SOD activity  MDA levels  NO levels 
Plasma  Myocardium  Plasma  Myocardium  Plasma  Myocardium 
Normal control group  133.27±7.29  368.51±44.33  11.56±4.49  2.22±1.06  110.83±16.88  10.35±1.89 
Diabetic control group  101.16±7.2**  238.69±24.42**  46.85±8.24**  8.41±1.91**  64.91±8.5**  4.66±1.28** 
SF-treated group  111.32±10.83** #  277.88±29.63** #  27.79±10.62** #  5.92±1.77** ##  80.97±17.43** #  8.49±1.27* ## 
Values are expressed as means ± SD (n=8 rats/group).  
SF, sodium ferulate; SOD, superoxide dismutase; MDA, malondialdehyde; NO, nitric oxide.  
*P<0.05, **P<0.01 compared with normal control group; #P<0.05, ##P<0.01 compared with diabetic control group. 
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Figure 2: Effect of SF on SOD activity in plasma (A) and myocardium (B). Values are expressed as means ± SD (n=8 rats/group). SF, 
sodium ferulate; SOD, superoxide dismutase. **P<0.01 compared with normal control group; #P <0.05 compared with diabetic control 
group. 
 
 
Figure 3: Effect of SF on MDA levels in plasma (A) and myocardium (B). Values are expressed as means ± SD (n=8 rats/group). SF, sodium 
ferulate; MDA, malondialdehyde. **P<0.01 compared with normal control group; #P<0.05, ##P<0.01 compared with diabetic control 
group. 
 
Plasma and myocardial NO levels in the diabetic 
control group were significantly lower than that in the 
normal control group (P<0.01). Plasma and myocar-
dial NO in SF-treated group were significantly higher 
than  that  in  the  diabetic  control  group  (P<0.05, 
P<0.01) (Fig. 4). 
Effect of SF on the expression of CTGF and 
iNOS in myocardium 
The yellow staining indicative of CTGF expres-
sion was prominent in myocardium in diabetic con-
trol group compared with that in the normal control 
group.  The  yellow  staining  indicative  of  CTGF  ex-
pression in myocardium in the SF-treated group was 
apparently  diminished  compared  with  that  in  the 
diabetic control group. The analysis of IOD showed 
that  CTGF  expression  was  significantly  higher  in 
myocardium in the diabetic control group compared 
with that in the normal control group (P<0.01), and 
that its expression  was notably reduced in  myocar-
dium in the SF-treated group compared with that in 
the diabetic control group (P<0.01). The results sug-
gest  that  treatment  with  SF  decreases  diabe-
tes-induced CTGF expression (Fig. 5).  
The yellow staining indicative of iNOS expres-
sion was prominent in myocardium in diabetic con-
trol group compared with that in the normal control 
group.  The  yellow  staining  indicative  of  iNOS  ex-
pression in myocardium in the SF-treated group was 
not apparently diminished compared with that in the Int. J. Med. Sci. 2012, 9 
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diabetic control group. The analysis of IOD showed 
that iNOS expression was significantly increased in 
myocardium in the diabetic control group compared 
with that in the normal control group (P<0.01), and 
that its expression was not notably reduced in myo-
cardium in the SF-treated group compared with that 
in  the  diabetic  control  group  (P>0.05).  The  results 
suggest  treatment  with  SF  did  not  inhibit  diabe-
tes-induced iNOS expression (Fig. 6).  
 
 
Figure 4: Effect of SF on NO level in plasma (A) and myocardium (B). Values are expressed as means ± SD (n=8 rats/group). SF, sodium 
ferulate; NO, nitric oxide. *P<0.05, **P<0.01 compared with normal control group; #P<0.05, ##P<0.01 compared with diabetic control 
group. 
 
 
Figure 5: Immunohistochemical staining for CTGF in myocardium (A: normal control group; B: diabetic control group; C: SF-treated 
group; D: Quantitation of CTGF expressed in IOD). SF, sodium ferulate; CTGF, connective tissue growth factor; IOD, integrated optical 
density. Original magnification ×100. **P<0.01 compared with normal control group; ##P<0.01 compared with diabetic control group. Int. J. Med. Sci. 2012, 9 
 
http://www.medsci.org 
297 
 
Figure 6: Immunohistochemical staining for iNOS in myocardium (A: normal control group; B: diabetic control group; C: SF-treated 
group; D: Quantitation of iNOS expressed in IOD). SF, sodium ferulate; iNOS, inducible nitric oxide synthase; IOD, integrated optical 
density. Original magnification ×100. **P<0.01 compared with normal control group. 
 
 
Ultrastructural examination by electron mi-
croscope  
Electron  micrographs  of  hearts  in  the  normal 
control group showed normal mitochondria profiles 
and  regular  myofibrillar  organization  with  evident 
M-lines and H-lines. In the hearts of the diabetic con-
trol group, sarcoplasm were prominent swelling, with 
disorganization and loss of myofibrils, destruction of 
M-lines and H-lines, inconformity of Z-bands thick-
ness, and loss of mitochondria. In the hearts of the 
SF-treated group, the abnormalities were significantly 
improved, indicating the cardioprotective effect of SF 
in diabetic rats (Fig. 7).  
Discussion 
There  have  been  large  numbers  of  studies  re-
porting  a  decrease  in  body  weight  in  diabetic  rats 
compared with normal control rats.18-20 However, as 
for the effects of SF on body weight and organ weight 
in diabetic rats, a consensus has not been reached. An 
increase in body weight by ferulic acid (FA) in dia-
betic rats was reported by Balasubashini MS et al.18 
Different from this increase effect, Fujita A et al re-
ported  that  there  were  no  significant  differences  in 
body  weight  and  kidney  weight  between  diabetic 
control  groups  and  FA-treated  groups,  although  an 
increase in kidney weight could be observed between 
diabetic  groups  and  normal  control  groups.19 
Thyagaraju BM et al pointed out a decrease in abso-
lute  testis  weight  and  an  increase  in  relative  testis 
weight, but FA treatment did not significantly affect 
the body weight gain and testicular weight of diabetic 
rats.20 In view of the results above, and considering 
the  different  animal  models  and  different  experi-
mental conditions, what we found is reasonable and 
could be understood. 
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Figure 7: Electron micrographs of myocardium (A: normal control group; B: diabetic control group; C: SF-treated group). SF, sodium 
ferulate. Original magnification ×10000. 
 
As many studies have reported, SF has a hypo-
glycemic  effect,  and  there  has  been  a  variety  of 
mechanisms  demonstrated  to  underlie  this  an-
ti-hyperglycemic effect. Jung EH et al reported three 
main mechanisms of the hypoglycemic effect of FA: 
inhibiting the activity of α-glucosidase and thus re-
ducing  glucose  absorption  from  the  small  intestine; 
increasing hepatic glucokinase activity and glycogen 
storage; elevating plasma insulin level.21 In a study by 
Balasubashini  MS  et  al,  they  showed  that  the  an-
ti-oxidant properties of FA decrease oxidative stress 
and toxicity on the pancreas caused by STZ, which 
could  help  the  beta  cells  to  proliferate  and  secrete 
more insulin, and thus lead to increased utilization of 
glucose  by  the  extra  hepatic  tissues  and  decreased 
blood glucose level.12,18 In our study, we did not no-
tice significant decrease in glucose levels by SF, this 
might  be  because  of  the  fluctuation  of  glucose  test 
strips we used. Some glucose values were high and 
others were low, which led to an unchanged result: 
being no significantly differences of the average blood 
glucose levels between SF-treated group and diabetic 
control group. 
As unwanted byproducts of aerobic metabolism, 
ROS are constantly generated in cells. Under normal 
physiological  conditions,  endogenous  antioxidant 
defense system in our body can effectively scavenge 
ROS and protect our body from damage induced by 
ROS.5,8 In diabetic condition, many mechanisms such 
as glucose autoxidation, protein glycation, defective 
mitochondria, increasing activity of cytosolic xanthine 
oxidase, production of mediators of inflammation, etc, 
contribute to the overproduction of ROS.22,23 Moreo-
ver, studies have showed antioxidant enzymes activi-
ties are decreased in diabetes.7,8 The serious imbalance 
between ROS production and the decline of antioxi-
dative ability leads to the enhancement of oxidative 
stress in diabetes. ROS can injury cell membrane, in-Int. J. Med. Sci. 2012, 9 
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duce  lipid  peroxidation,  and  increase  membrane 
permeability,  which  can  significantly  lead  to  cells 
functional and structural abnormalities, even death.4-8 
Recently, study also showed that ROS can augment 
myocardial  fibrosis  in  diabetes.24  In  diabetes,  these 
changes can cause myocardial remodeling, lead to the 
occurrence and development of DC. Antioxidant en-
zymes  in  our  body  include  superoxide  dismutase 
(SOD),  catalase  (CAT)  and  glutathione  peroxidase. 
SOD, which can effectively scavenge superoxide rad-
icals, is the most important antioxidant enzyme in our 
body. Shen’s study showed overexpression of man-
ganese superoxide dismutase (MnSOD) to the heart 
can protect heart from oxidative damage in diabetic 
mice.7 SF is an effective antioxidant. Previous studies 
have demonstrated SF can inhibit oxidative stress and 
lipid  peroxidative  reaction,  increase  antioxidant  en-
zymes activity, and exhibit beneficial roles in many 
diseases.12,14 Our results in the study showed that SF 
can increase SOD activity in plasma and myocardium, 
and decrease the level of MDA in plasma and myo-
cardium in diabetic rats. 
The role of NO and NOS in DC are unclear at 
present. In the heart, the principal isoenzymes of NOS 
that produce NO are eNOS and iNOS, both of which 
are present in cardiac myocytes and vascular endo-
thelium  cells.5,25  Moderate  levels  of  NO,  which  is  a 
cardioprotective factor and can inhibit cell apoptosis, 
maintain the function of heart, is mainly produced by 
eNOS  under  normal  physiological  conditions.26,27 
However, iNOS is implicated in diabetes-related heart 
dysfunctions.26,27 Several studies have shown that the 
expression of iNOS in myocardium in diabetes is up-
regulated, but the levels of NO are decreased or un-
altered.28-30 NO is very reactive and excessive produc-
tion of NO in the heart of diabetes may be quickly 
scavenged by free radicals such as superoxide anions, 
and at the same time, leads to the formation of per-
oxynitrite, which has dramatic propathogenic effects 
in the heart in diabetes (in addition to oxidizing pro-
teins,  peroxynitrite  also  causes  lipid  peroxidation 
which can lead to cellular damage).4,5 This is the rea-
son why levels of NO are decreased or unaltered in 
the heart of diabetes. Diabetic rats administrated by 
iNOS inhibitor or diabetic mice targeted deletion of 
the gene for iNOS exhibit improved heart function, 
which  suggested  that  NO,  superoxide  anions  and 
their reaction product, peroxynitrite, play important 
roles in DC.26,27 Because of the molecular structure of 
NO,  regardless  produced  by  eNOS  or  iNOS,  is  the 
same. It is plausible that NO itself can’t damage heart 
in diabetes. Peroxynitrite, the reaction product of NO 
and  ROS,  is  the  archcriminal  and  can  damage  the 
heart in diabetes. Our study showed that the expres-
sion of iNOS in myocardium was significantly higher 
in diabetic rats, but Plasma and myocardial NO in the 
diabetic control group were significantly lower than 
that in the normal control group. This is because that, 
although increased iNOS caused increased NO, ele-
vated ROS at the same time could interact with NO 
and  result  in  its  ultimate  decrease  in  diabetic  rats. 
What is more, the present study suggests SF can not 
influence the expression of iNOS in the heart in dia-
betic rats. Also, SF can not increase NO levels directly. 
However, it seemed that the NO levels were indeed 
elevated in SF-treated group compared with that in 
diabetic control group. The truth is, SF can increase 
the activity of SOD and decrease the production of 
ROS. The quantity of NO scavenged by ROS is de-
creased, which leads to the increase of NO levels in 
myocardium in SF-treated group. In other words, SF 
increase NO levels indirectly by decreasing the pro-
duction of ROS and thus decreasing the interaction of 
NO and ROS. 
CTGF is increasingly being implicated in struc-
tural and functional abnormality of the heart in dia-
betes.31 CTGF is a potent profibrotic protein and play 
important roles in tissue and organ fibrosis.32 CTGF 
expression has been shown to correlate with the se-
verity and progression of fibrosis in multiple fibrotic 
diseases.32  CTGF  has  diverse  biological  actions  in-
cluding the regulation of fibroblast proliferation, an-
giogenesis  collagen  synthesis,  extracellular  matrix 
deposition, and cellular apoptosis.32 The expression of 
CTGF  is  increased  in  the  myocardium  of  rats  with 
STZ-induced diabetes.31 Hyperglycemia, ROS, angio-
tensin II, vascular endothelial growth factor, protein 
kinase C, transforming growth factor-β (TGF-β), ad-
vanced  glycation  end  products  can  up-regulate  the 
expression  of  CTGF.31,33 Our  study  showed  the  ex-
pression of CTGF in myocardium in the diabetic con-
trol group was significantly increased compared with 
the normal control group. But the expression of CTGF 
in the SF-treated group was significantly lower than 
that in the diabetic control group. It may be one of the 
mechanisms of cardioprotective effect of SF in diabe-
tes.  
In  summary,  the  present  study  demonstrated 
that  SF  has  a  cardioprotective  effect  via  increasing 
SOD activity and NO levels in plasma and myocar-
dium, inhibiting oxidative stress in plasma and myo-
cardium, and inhibits the expression of CTGF in my-
ocardium  in  diabetes  rats.  SF  may  be  used  for  the 
treatment of DC. 
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